DECICCO CARL 4
4 · Foghorn Therapeutics Inc. · Filed Dec 13, 2021
Insider Transaction Report
Form 4
DECICCO CARL
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2021-12-09$3.72/sh+104,310$388,033→ 362,707 total - Exercise/Conversion
Stock Options (Right to buy)
2021-12-09−27,418→ 34,273 totalExercise: $3.72Exp: 2029-02-20→ Common Stock (27,418 underlying) - Exercise/Conversion
Stock Options (Right to buy)
2021-12-09−76,892→ 186,571 totalExercise: $3.72Exp: 2029-02-20→ Common Stock (76,892 underlying)
Footnotes (2)
- [F1]The option vested as to 25% of the underlying shares of common stock on December 10, 2019, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested.
- [F2]The option vested as to 25% of the underlying shares of common stock on January 30, 2020, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested.